PI3Kδ 抑制在 B 细胞恶性肿瘤中击中敏感点。

PI3Kδ inhibition hits a sensitive spot in B cell malignancies.

机构信息

UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.

出版信息

Cancer Cell. 2014 Mar 17;25(3):269-71. doi: 10.1016/j.ccr.2014.02.012.

DOI:10.1016/j.ccr.2014.02.012

Abstract

A PI3Kδ-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas. In these malignancies, the PI3K pathway is not mutationally activated as in many other cancers, but it is important for mediating supportive cues from the cancer microenvironment and the B cell antigen receptor.

摘要

一种 PI3Kδ 选择性抑制剂在慢性淋巴细胞白血病和惰性 B 细胞非霍奇金淋巴瘤中显示出令人印象深刻的临床活性。在这些恶性肿瘤中，PI3K 途径不像许多其他癌症那样发生突变激活，但它对于介导来自癌症微环境和 B 细胞抗原受体的支持信号很重要。